Actually after listening to the conference call, I realized that those PD1 melanoma refractory patients may not have been ever treated with ipilumab before this trial. My assumption may not have been correct unless that lady scientist gave a clarification on what the prior treatment of those patients were before entering this trial. At this point, I'd have to wait for their other arm to enroll and see the data for the pembro combo trial to see if any efficacy is due to the imo-2125. At this point in time, the current efficacy simply could be due to ipil and nothing to do with IMO2125.
JMHO
News 
Market Data 
Discover 
